The TEGSEDI-PRG pregnancy observational study was developed by Akcea Therapeutics, Inc. to follow patients who have been exposed to at least one dose of TEGSEDI® (inotersen) during their pregnancy (or patients who became pregnant within 25 weeks of taking TEGSEDI). The purpose of this study is to learn more about the health of pregnant women who are taking or have taken TEGSEDI and the health of their babies.
Pregnant women with the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR-PN), who have not been exposed to TEGSEDI, are also eligible for this observational pregnancy study.
Your participation in this study will help Akcea Therapeutics Inc. to gather more information that could help women in the future and their doctors make more informed decisions.
You are eligible to participate in either of the two scenarios outlined below:
You have taken at least 1 dose of TEGSEDI during your pregnancy or within 25 weeks of becoming pregnant;
You have the polyneuropathy of hereditary transthyretin amyloidosis (hATTR-PN) and you are pregnant.